Research programme: allosteric Akt inhibitors - Almac Discovery

Drug Profile

Research programme: allosteric Akt inhibitors - Almac Discovery

Alternative Names: ALM 301

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Almac Discovery
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jul 2017 Discontinued - Preclinical for Cancer in United Kingdom (Almac discovery communication and pipeline, July 2017)
  • 27 Jul 2016 Preclinical development is ongoing for Cancer in United Kingdom (Almac Discovery pipeline, July 2016)
  • 27 Jul 2016 ALM 301 is available for licensing (www.almacgroup.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top